KALV
KalVista Pharmaceuticals, Inc.

Market cap $116.9M
Enterprise value $89.145M
Employees 28
Revenue $1.59M
EBITDA -$18.1M
Income -$21.9M
EPS -2.38
P/E N/A
Forward P/E -7.74
EV/EBITDA -4.93
PEG N/A
Earnings date N/A
Volume 1.61k / 68.6k
Relative vol. 0.02 ×
Profit margin 0.00%
Oper. margin -1,147.16%
Gross margin 94.83%
Ret. on assets -47.22%
Return on equity -101.42%
Sales Q/Q 16,000.00%
Sales Y/Y 10,692.86%
Est. EPS Q/Q N/A
Beta N/A
Mean Recomm. 1.00
IPO year 2015
Country United States
RSI 46.54
Range $10.79 – $11.23
52 weeks $5.48 – $15.80
SMA 50 $11 -1.53%
SMA 200 $10 -12.98%
1 year target $27 +146.58%

Intraday

5 days

1 month

3 months

6 months

1 year

5 years

10 years

All time

Date
#
Company
Insider Title
Trans.
Transaction
Shares Price per share Total price Shares after Source
2017-10-10 Holdings A/S Novo
10% owner
10% owner Sale 2,725,283 $9.64 $26,271,728
2017-10-10
0
2017-09-13 Holdings A/S Novo
10% owner
10% owner Sale 176,647 $7.21 $1,273,625
2017-09-13
2,725,280

Notable SEC filings of KalVista Pharmaceuticals, Inc.

Date Contents
Source
2017-09-28 8-K Submission of Matters to a Vote of Security Holders
2017-09-14 10-Q Quarterly report
2017-09-14 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2017-08-25 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
2017-07-27 10-K Yearly report
2017-07-27 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2017-07-13 8-K Entry into a Material Definitive Agreement; Financial Statements and Exhibits
2017-05-30 8-K Entry into a Material Definitive Agreement
2017-03-27 8-K Submission of Matters to a Vote of Security Holders
2017-03-17 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2017-03-16 10-Q Quarterly report
2016-11-23 8-K Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Unregistered Sales of Equity Securities; Material Modifications to Rights of Security Holders; Changes in Registrant's Certifying Accountant; Changes in Control of Registrant; Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Financial Statements and Exhibits
2016-11-21 8-K Submission of Matters to a Vote of Security Holders
2016-11-08 10-Q Quarterly report
2016-11-04 8-K Other Events
2016-09-30 8-K Other Events
2016-08-12 10-Q Quarterly report
2016-07-29 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
2016-06-28 8-K Termination of a Material Definitive Agreement
2016-06-24 8-K Regulation FD Disclosure; Other Events; Financial Statements and Exhibits
2016-06-22 8-K Regulation FD Disclosure; Other Events; Financial Statements and Exhibits
2016-06-17 8-K Submission of Matters to a Vote of Security Holders
2016-06-15 8-K Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement; Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Unregistered Sales of Equity Securities; Other Events; Financial Statements and Exhibits
2016-05-12 10-Q Quarterly report
2016-04-18 8-K Cost Associated with Exit or Disposal Activities; Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Other Events; Financial Statements and Exhibits
2016-03-30 10-K Yearly report

KalVista Pharmaceuticals executives

Insider Title Age Since Compensation
Edward Unkart (67)
Independent Director since 2014
Independent Director 67 2014
Albert Cha (45)
Independent Director since 2007
Independent Director 45 2007
Rajeev Shah (40)
Director since 2016
Director 40 2016
Joshua Resnick (42)
Director since 2016
Director 42 2016
Arnold Oronsky (77)
Director since 2016
Director 77 2016
Christopher Yea (53)
Chief Development Officer since 2016
Chief Development Officer 53 2016
Benjamin Palleiko (51)
Chief Financial Officer since 2016
Chief Financial Officer 51 2016
Thomas Crockett (42)
Chief Executive Officer, Director since 2016
Chief Executive Officer, Director 42 2016
Richard Aldrich (63)
Chairman of the Board since 2016
Chairman of the Board 63 2016
KalVista Pharmaceuticals, Inc. logo

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products under development include KVD818, an orally delivered molecule that is in Phase I clinical trial for the treatment of HAE; KVD001, an intravitreally administered plasma kallikrein inhibitor that has completed a Phase I clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein that is in preclinical safety studies for use against human proteases related to plasma kallikrein. The company is headquartered in Cambridge, Massachusetts.

  • KalVista Pharmaceuticals, Inc., Building 200, Cambridge 02139, United States
  • kalvista.com
  • 857-999-0075

Quarterly EPS estimates

Profit margin

Debt to assets

Cash flow

Balance sheet

(in millions) 2017Q3 2017Q2 2017Q2 2016Q3
Current assets
Cash $28.128 $26.456 $30.95 $35.208
Short term investments
Net receivables $4.611 $2.895 $2.547
Inventory
Other current assets $1.4 $0.841 $0.751 $0.605
Total current assets $34.139 $30.192 $34.248 $35.813
Long term investments
Property, plant & equipment $0.602 $0.592 $0.097
Goodwill
Intangible assets
Other assets $0.05
Deferred long term asset charges
Total assets $34.741 $30.784 $34.345 $35.863
Current liabilities
Accounts payable $3.293 $3.635 $3.018 $1.862
Short long term debt $0.22 $0.202
Other current liabilities $0.029
Total current liabilities $3.513 $3.837 $3.018 $1.891
Long term debt $0.149 $0.213
Other liabilities
Deferred long term liabilities $0.035
Minority interest
Total liabilities $3.662 $4.05 $3.018 $1.926
Stockholders' equity
Stock option warrants
Common stock $0.011 $0.01 $0.01 $0.027
Retained earnings -$65.769 -$60.784 -$55.855 -$88.963
Treasury stock
Capital surplus $99.408 $90.036 $89.815 $122.873
Other stockholder equity -$2.571 -$2.528 -$2.643
Total stockholder equity $31.079 $26.734 $31.327 $33.937
Net tangible assets $31.079 $26.734 $31.327 $33.937
(in millions) 2017 2016 2016
Current assets
Cash $30.95 $48.455 $48.455
Short term investments
Net receivables $2.547 $2.239 $2.239
Inventory
Other current assets $0.751 $1.01 $1.01
Total current assets $34.248 $49.465 $49.465
Long term investments
Property, plant & equipment $0.097 $0.16 $0.16
Goodwill
Intangible assets
Other assets $0.05 $0.05
Deferred long term asset charges
Total assets $34.345 $49.675 $49.675
Current liabilities
Accounts payable $3.018 $1.875 $1.875
Short long term debt $1.95 $1.95
Other current liabilities $0.029 $0.029
Total current liabilities $3.018 $3.854 $3.854
Long term debt $2.701 $2.701
Other liabilities
Deferred long term liabilities $0.049 $0.049
Minority interest
Total liabilities $3.018 $6.604 $6.604
Stockholders' equity
Stock option warrants $58.608 $58.608
Common stock $0.01 $0.027 $0.027
Retained earnings -$55.855 -$79.228 -$79.228
Treasury stock
Capital surplus $89.815 $122.272 $122.272
Other stockholder equity -$2.643 -$0.075 -$0.075
Total stockholder equity $31.327 $43.071 $43.071
Net tangible assets $31.327 $43.071 $43.071

Income statement

(in millions) 2017Q3 2017Q2 2017Q2 2016Q3
Revenue
Total revenue $1.127 $0.096 $0.114 $0.007
Cost of revenue
Gross profit $1.127 $0.096 $0.114 $0.007
Operating expenses
Research & development $4.361 $3.476 $2.996 $0.332
Selling, general & administrative $2.703 $2.073 $2.204 $2.08
Non-recurring
Other operating expenses
Total operating expenses
Operating income -$5.937 -$5.453 -$5.086 -$2.405
Income from continuing operations
Net other income $0.951 $0.525 $0.884 $0.019
EBIT -$4.986 -$4.928 -$4.202 -$2.386
Interest expense
Income before tax -$4.986 -$4.928 -$4.202 -$2.386
Income tax expense
Minority interest
Net income from continuing ops -$4.986 -$4.928 -$4.202 -$2.386
Non-recurring events
Discontinued operations
Extraordinary items
Effect of accounting change
Other items
Net income
EBITDA -$4.986 -$4.928 -$4.202 -$2.386
Income (for common shares) -$4.986 -$4.928 -$4.202 -$2.386
(in millions) 2017 2016 2016
Revenue
Total revenue $1.504 $0.007 $0.007
Cost of revenue
Gross profit $1.504 $0.007 $0.007
Operating expenses
Research & development $12.666 $3.532 $3.532
Selling, general & administrative $11.177 $1.543 $1.543
Non-recurring $1.46 $1.46
Other operating expenses
Total operating expenses
Operating income -$22.339 -$6.528 -$6.528
Income from continuing operations
Net other income $3.736 $0.009 $0.009
EBIT -$18.603 -$6.519 -$6.519
Interest expense $0.088 $0.088
Income before tax -$18.603 -$6.607 -$6.607
Income tax expense
Minority interest
Net income from continuing ops -$18.603 -$6.607 -$6.607
Non-recurring events
Discontinued operations
Extraordinary items
Effect of accounting change
Other items
Net income
EBITDA -$18.603 -$6.607 -$6.607
Income (for common shares) -$18.603 -$6.607 -$6.607

Cash flow

(in millions) 2017Q3 2017Q2 2017Q2 2016Q3
Net income -$4.986 -$4.928 -$4.202 -$2.386
Operating activities
Depreciation $0.047 $0.032 $0.011 $0.011
Net income adjustments $0.272 $0.253 $0.259 $0.282
Change in accounts receivable -$1.681 -$0.306 $0.696 $0.696
Changes in liabilities -$0.36 $0.586 -$0.013 -$0.045
Changes in inventory
Changes in other operating activities -$0.551 -$0.085 $0.608 $0.533
Total cash flow from operations -$7.259 -$4.448 -$2.641 -$1.616
Investing activities
Capital expenditures -$0.051 -$0.11 -$0.007 -$0.007
Investments
Other cash flows from investing
Total cash flows from investing -$0.051 -$0.11 -$0.007 -$0.007
Financing activities
Dividends paid
Sale and purchase of stock $9.1 $9.1 $9.1 $0.005
Net borrowings -$0.049 -$0.049 -$0.049 -$0.049
Other cash flows from financing
Total cash flows from financing $9.051 $9.051 $9.051 $0.005
Effect of exchange rate -$0.069 $0.064 $0.1 $0.1
Change in cash and equivalents $1.672 -$4.494 -$2.548 -$1.611
(in millions) 2017 2016 2016
Net income -$18.603 -$6.607 -$6.607
Operating activities
Depreciation $0.04 $0.041 $0.041
Net income adjustments -$0.977 $1.863 $1.863
Change in accounts receivable -$0.571 -$1.285 -$1.285
Changes in liabilities -$3.53 -$0.525 -$0.525
Changes in inventory
Changes in other operating activities -$0.081 $0.144 $0.144
Total cash flow from operations -$23.722 -$5.084 -$5.084
Investing activities
Capital expenditures -$0.074 -$0.184 -$0.184
Investments
Other cash flows from investing $34.139 $34.139 $34.139
Total cash flows from investing $34.065 -$0.184 -$0.184
Financing activities
Dividends paid
Sale and purchase of stock $0.002 $33.003 $33.003
Net borrowings
Other cash flows from financing
Total cash flows from financing $0.002 $0.002 $0.002
Effect of exchange rate -$1.159 -$0.598 -$0.598
Change in cash and equivalents $9.186 -$5.268 -$5.268
Messenger